Abstract
The purpose of the study was to compare the two mucin secretogogues, diquafosol (DQS) and rebamipide (RBM), for the treatment of dry eye syndrome (DES) in office workers. Dry eye patients using computers for >4 h/day were randomly assigned treatment with either DQS or RBM. Main outcomes measures included changes in tear film break-up time (TBUT) and subjective symptoms assessed by the Dry Eye-Related Quality of Life Score (DEQS). The subjects had scheduled examinations at 0 and 4 weeks, and the examinations at 2 and 8 weeks were optional. Changes in keratoconjunctival fluorescein score and a patient satisfaction questionnaire were also recorded. Both groups showed significant improvements in the DEQS scores at 2, 4, and 8 weeks following the initiation of the study. Both groups showed significant increases in the TBUT at 2 and 4 weeks. No significant difference was found between the DQS and RBM groups at any time periods. Patients reported more comfort with the use of DQS compared with the use of RBM. No local or systemic side effects were noted. The results of the present study indicated that both DQS and RBM were effective for the treatment of DES in office workers.
Highlights
(4-chlorobenzoylamino)-3- (2-oxo-1,2-dihydroquinolin-4-yl) propanoic acid] have recently become commercially available in Japan
Office workers are exposed to numerous risk factors for dry eye syndrome (DES)
A recent study reported that sedentary behavior and the resulting metabolic syndrome were risk factors for DES5,8
Summary
(4-chlorobenzoylamino)-3- (2-oxo-1,2-dihydroquinolin-4-yl) propanoic acid] have recently become commercially available in Japan. While both formulations increase tear film mucins, they have different mechanisms of action. Uchino Y recently reported that RBM increased MUC 16 protein synthesis in human corneal epithelial cells[26]. RBM has been shown to have antiinflammatory effects[27,28,29] Both drugs have been reported to be effective for various kinds of DES including Sjogren’s syndrome, non-Sjogren’s www.nature.com/scientificreports/. We conducted a prospective, randomized, clinical trial to determine the efficacy and safety of DQS and RBM for the treatment of DES in office workers that used computers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
